- Home
- DHI vs INSM Comparison
DHI vs INSM Comparison
Compare DHI & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHI
- INSM
- Stock Information
- Founded
- DHI 1978
- INSM 1988
- Country
- DHI United States
- INSM United States
- Employees
- DHI N/A
- INSM N/A
- Industry
- DHI Homebuilding
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- DHI Consumer Discretionary
- INSM Health Care
- Exchange
- DHI Nasdaq
- INSM Nasdaq
- Market Cap
- DHI 42.6B
- INSM 40.7B
- IPO Year
- DHI 1992
- INSM 2000
- Fundamental
- Price
- DHI $142.50
- INSM $193.63
- Analyst Decision
- DHI Buy
- INSM Strong Buy
- Analyst Count
- DHI 13
- INSM 19
- Target Price
- DHI $160.08
- INSM $171.12
- AVG Volume (30 Days)
- DHI 2.9M
- INSM 2.3M
- Earning Date
- DHI 10-28-2025
- INSM 10-30-2025
- Dividend Yield
- DHI 1.26%
- INSM N/A
- EPS Growth
- DHI N/A
- INSM N/A
- EPS
- DHI 11.57
- INSM N/A
- Revenue
- DHI $34,250,400,000.00
- INSM $447,022,000.00
- Revenue This Year
- DHI $1.60
- INSM $40.09
- Revenue Next Year
- DHI $5.77
- INSM $129.64
- P/E Ratio
- DHI $12.31
- INSM N/A
- Revenue Growth
- DHI N/A
- INSM 30.34
- 52 Week Low
- DHI $110.44
- INSM $60.40
- 52 Week High
- DHI $184.55
- INSM $197.08
- Technical
- Relative Strength Index (RSI)
- DHI 31.96
- INSM 69.89
- Support Level
- DHI $142.30
- INSM $182.53
- Resistance Level
- DHI $148.22
- INSM $189.31
- Average True Range (ATR)
- DHI 3.97
- INSM 8.01
- MACD
- DHI -0.15
- INSM 0.32
- Stochastic Oscillator
- DHI 2.39
- INSM 89.27
About DHI D.R. Horton Inc.
With operations in 126 markets across 36 states, D.R. Horton is the leading homebuilder in the United States. It mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.